iTeknik Holding Corporation (ITKH): Hey Benosufan, jc have you received any...

Hey Benosufan, jc have you received any additional

Id_stocks · 2023-02-18T15:30:33.2100000Z

Hey Benosufan, jc have you received any additional communication from the receiver?

Play Episode

5min

Proactive - Interviews for investors

Gaming Realms CEO on 2024 successes, Slingo growth and 2025 outlook

Gaming Realms PLC CEO Mark Segal takes Proactive's Stephen Gunnion through the company's strong 2024 financial performance and its ongoing international expansion. The company reported a year of strong growth, with revenue rising in both core content licensing and non-core social segments. Segal highlighted a “revenue increase, increase in our core content licensing business,” alongside gains in adjusted EBITDA and net profit, underlining operational leverage within the business. The company's flagship Slingo titles drove momentum, with 12 new releases in 2024 and North America contributing 54% of licensing revenue. “The cohorts of games we built in 2024 has probably been our highest-grossing sets of games in the first year,” said Segal. Gaming Realms is now live in five regulated U.S. states and recently launched in Brazil, aiming to deepen its presence in both. Segal also discussed the addition of third-party studio content, including Real Play, For The Player, and upcoming partner S Gaming, helping diversify offerings and penetrate high-barrier markets like the U.S. Cash generation remains strong, with a £13.5 million balance and a share buyback program underway. Looking ahead, Segal said the company expects continued organic growth, expansion into South Africa, and new launches with British Columbia’s lottery. Visit Proactive's YouTube channel for more investor-focused interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #GamingRealms #Slingo #OnlineGaming #iGaming #GamingStocks #GamingInvestments #NorthAmericaGaming #BrazilGamingMarket #DigitalGames #InvestorUpdate #CashGenerative #LicensingRevenue #StockMarketNews

Proactive - Interviews for investors

Zinnwald Lithium wins Saxony government endorsement for lithium project after robust PFS

Zinnwald Lithium PLC (LSE:ZNWD, OTC:ZNWLF) chief executive Anton du Plessis talked with Proactive's Stephen Gunnion about the company’s recently published pre-feasibility study (PFS) for its Zinnwald Lithium Project, located in Saxony, Germany. The project is designed to supply battery-grade lithium hydroxide to the European market and has now received public backing from the Saxony government. Du Plessis outlined that the PFS demonstrates a scalable, long-life mining operation, starting with 18,000 tonnes per annum of lithium hydroxide and potentially scaling to 35,000 tonnes in a second phase. He stated, “We published our PFS on Monday that showed an economic project of significant scale… a globally significant project in terms of scale.” The economics were highlighted as robust, with a post-tax NPV of €2.20 billion and an internal rate of return of approximately 20%. The location of the project — 35km south of Dresden — positions it strategically at the heart of Germany and the EU, aligning with Europe’s push for regional supply chains of critical raw materials. Du Plessis also emphasised the importance of the local endorsement, noting, “To have the public endorsement, as we had, is extremely important to us.” The next step for the company is to optimise the project in preparation for a Definitive Feasibility Study, expected in 2026. Visit Proactive's YouTube channel for more interviews like this. Don't forget to like this video, subscribe to the channel, and hit the notification bell to stay updated on future content. #Lithium #BatteryMetals #ZinnwaldLithium #GermanMining #Saxony #CriticalMinerals #EVsupplychain #LithiumHydroxide #EUrawmaterials #MiningInvestment #PFS #CleanEnergy #ZinnwaldProject

Proactive - Interviews for investors

Abacus Global Management CEO on 2024 highlights and 2025 targets

Abacus Global Management (NASDAQ:ABL) CEO Jay Jackson takes Proactive's Stephen Gunnion through the company’s strong financial performance in 2024 and its strategic outlook for 2025. The pioneering alternative asset manager reported 69% year-over-year revenue growth for 2024, with the fourth quarter alone seeing a 40% increase. Jackson noted that 2023 was already a record year, and 2024 surpassed that benchmark by over 50%. The company has issued guidance for 2025 that anticipates adjusted net income to rise by between 51% and 68%, driven by continued demand for non-correlated assets. Founded over 20 years ago, Abacus recently rebranded from Abacus Life to better reflect its identity as an alternative asset manager. Jackson explained, “We're an asset manager... and we also own a large institutional asset manager in Luxembourg,” underlining the firm’s expanding global footprint. Growth drivers include strategic acquisitions, expansion of its financial advisor channel, and development in its technology division. Jackson emphasized the role of AI in analyzing health and lifespan data to support financial planning, stating, “Think about the billion scenarios in someone's lifespan… AI helps us understand more accurate outcomes.” Jackson believes 2025 will bring increasing attention to the firm’s asset management operations, complementing its origination and technology capabilities. For more interviews like this, visit Proactive’s YouTube channel. Don’t forget to like this video, subscribe to the channel, and turn on notifications to stay updated. #AbacusGlobal #AlternativeAssets #JayJackson #AssetManagement #LifeInsuranceInvesting #AIinFinance #FinancialPlanning #SmallCapStocks #2025Outlook #InvestorInsights #NonCorrelatedAssets #TechInFinance

Proactive - Interviews for investors

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones

Trevi Therapeutics CEO Jennifer Good joined Steve Darling from Proactive to discuss the company’s progress in advancing its cough treatment pipeline using nalbuphine, a mixed agonist-antagonist opioid. Originally developed for acute indications, nalbuphine is now being repurposed due to its dual mechanism of action, working both peripherally in the lungs and centrally in the brainstem, offering a novel approach to treating chronic cough disorders. Trevi initially explored multiple indications, including skin conditions caused by severe itching and neurological cough. However, compelling clinical data led the company to focus on cough-related indications. Good explained, “We thought our drug was different because not only does it work peripherally in the lung, it works centrally at the brain, which mediates coughing and breathing.” The company is now targeting three key areas: interstitial lung diseases (including idiopathic pulmonary fibrosis, or IPF), refractory chronic cough (RCC), and other neurological cough conditions. Following promising Phase 2a results in RCC—an area where many previous drug candidates have failed—Trevi is preparing for a Phase 2b dose-ranging study. If successful, only one pivotal study may be required before regulatory filing. Good also highlighted Trevi’s strong financial position, noting that the company has sufficient cash runway to support its current studies through the second half of 2026, including further development in RCC and IPF. #proactiveinvestors #trevitherapeuticsinc #nasdaq #trvi #JenniferGood #Nalbuphine #ChronicCough #RefractoryCough #Phase2aResults #BiotechNews #PharmaPipeline #IPF #ClinicalTrials #CoughTreatment #NeurologicalDisorders #ProactiveInvestors

Followers	3
Posts	479
Boards Moderated	0
Alias Born	03/12/2018

Volume:	-
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

ITKH Detailed Quote

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Go Ad-Free